Copyright
©The Author(s) 2015.
World J Hepatol. Jun 28, 2015; 7(12): 1606-1616
Published online Jun 28, 2015. doi: 10.4254/wjh.v7.i12.1606
Published online Jun 28, 2015. doi: 10.4254/wjh.v7.i12.1606
Cirrhosis CP A, all HCV genotypes | ||
Sofosbuvir + RBV until LT | Peg-IFN + RBV + sofosbuvir for 12 wk | RBV + sofosbuvir + daclatasvir for 12 wk |
Cirrhosis CP B and C, all HCV genotypes | ||
Sofosbuvir + RBV until LT | IFN contraindicated | RBV + sofosbuvir + daclatasvir for 12 wk |
- Citation: Pipili C, Cholongitas E. Treatment of chronic hepatitis C in liver transplant candidates and recipients: Where do we stand? World J Hepatol 2015; 7(12): 1606-1616
- URL: https://www.wjgnet.com/1948-5182/full/v7/i12/1606.htm
- DOI: https://dx.doi.org/10.4254/wjh.v7.i12.1606